344860 — Innogene Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesSpeculativeMicro CapFalling Star

Annual income statement for Innogene Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Interim Report	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	—	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	9,385	9,139	10,101	8,945	8,213
Cost of Revenue
Gross Profit	7,324	6,787	7,329	6,635	6,219
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	6,986	7,652	8,875	8,314	8,209
Operating Profit	2,399	1,488	1,226	630	4.49
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	2,436	1,545	1,706	1,123	257
Provision for Income Taxes
Net Income After Taxes	2,258	1,339	1,396	945	288
Net Income Before Extraordinary Items
Net Income	2,258	1,339	1,396	945	288
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,258	1,339	1,396	945	288
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	243	144	120	79.6	25.5
Dividends per Share